Pulmonary arterial hypertension associated with congenital heart disease

Pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD) is a condition in which abnormally high blood pressure develops in the pulmonary arteries — the blood vessels that carry blood from the heart to the lungs — as a consequence of underlying structural heart defects present from birth. Congenital heart defects that involve left-to-right shunts, such as ventricular septal defects, atrial septal defects, patent ductus arteriosus, and atrioventricular septal defects, can lead to increased blood flow and pressure in the pulmonary vasculature. Over time, this excess flow causes progressive remodeling and narrowing of the small pulmonary arteries, resulting in elevated pulmonary vascular resistance. If left untreated, the condition can progress to Eisenmenger syndrome, in which the shunt reverses direction (becoming right-to-left), leading to cyanosis and systemic oxygen desaturation. Key symptoms include progressive shortness of breath (dyspnea), exercise intolerance, fatigue, chest pain, palpitations, syncope (fainting), and in advanced cases, cyanosis (bluish discoloration of the skin and lips). Patients may also develop signs of right heart failure, including peripheral edema, hepatomegaly, and ascites. The severity and timing of symptom onset depend on the type and size of the congenital heart defect, with large unrepaired defects typically leading to earlier and more severe pulmonary vascular disease. Management of PAH-CHD involves a multidisciplinary approach. Surgical or interventional repair of the congenital heart defect may be performed if pulmonary vascular disease has not yet become irreversible. For patients with established PAH, targeted pulmonary vasodilator therapies are used, including endothelin receptor antagonists (e.g., bosentan, macitentan), phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil), and prostacyclin pathway agents (e.g., epoprostenol, iloprost). Supportive measures include oxygen therapy, diuretics, and anticoagulation in selected cases. In advanced refractory disease, lung transplantation or combined heart-lung transplantation may be considered. Regular monitoring at specialized pulmonary hypertension centers is essential for optimal outcomes.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Pulmonary arterial hypertension associated with congenital heart disease